Archives

  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2018-07

    • miR-18a/ALOXE3 Axis Links Ferroptosis and Migration in GBM

    2026-06-06

    Dissecting the miR-18a/ALOXE3 Axis: Ferroptosis Suppression and Enhanced Migration in Glioblastoma

    Study Background and Research Question

    Glioblastoma multiforme (GBM) ranks among the most aggressive and fatal brain tumors, with median survival for patients rarely surpassing 15 months, even under multimodal therapy. The limited efficacy of existing treatments underscores the need for deeper molecular understanding of GBM pathogenesis and for the identification of actionable therapeutic targets. Accumulating evidence suggests that alterations in cellular lipid metabolism and non-coding RNA regulation play pivotal roles in tumor development, therapy resistance, and malignant progression. However, the interplay between these processes in GBM remains incompletely defined.

    The reference study, Yang et al. (2021), addresses this gap by investigating how the microRNA miR-18a modulates GBM progression through its effects on the lipoxygenase ALOXE3, and how these molecular events impact ferroptosis (a non-apoptotic, iron-dependent form of cell death) and tumor cell migration. The overarching research question centers on elucidating the miR-18a/ALOXE3 axis and its role in shaping the vulnerability of GBM cells to ferroptosis and their propensity for invasive behavior.

    Key Innovation from the Reference Study

    The central innovation of the study lies in the identification of a direct mechanistic link between miR-18a-mediated repression of ALOXE3 and downstream effects on ferroptosis sensitivity and cell migration in GBM. While previous research has implicated various lipoxygenases in cancer biology, the functional consequences of ALOXE3 down-regulation in GBM, particularly as a target of miR-18a, had not been characterized. This work demonstrates that miR-18a is upregulated in GBM and directly targets ALOXE3, resulting in reduced expression and activity of this enzyme. The suppression of ALOXE3, in turn, decreases susceptibility to p53-SLC7A11-dependent ferroptosis and promotes the secretion of 12-hydroxyeicosatetraenoic acid (12-HETE), fostering autocrine activation of pro-migratory signaling pathways. By linking a specific microRNA, a lipid metabolic enzyme, and a regulated cell death pathway, this research provides new molecular insights into GBM progression and suggests potential points of therapeutic intervention.

    Methods and Experimental Design Insights

    To dissect the miR-18a/ALOXE3 pathway, the study employed a combination of molecular, cellular, and in vivo approaches:

    • Gene expression profiling: Quantitative RT-PCR and Western blot analyses were used to assess miR-18a and ALOXE3 expression in GBM patient samples and cell lines.
    • Functional manipulation: Loss- and gain-of-function experiments were conducted using miR-18a mimics, inhibitors, and ALOXE3-specific siRNA or overexpression constructs in GBM cell lines to evaluate the effects on cell viability, ferroptosis sensitivity, and migration.
    • Ferroptosis assays: The impact of ALOXE3 modulation on cell death was assessed using ferroptosis-inducing agents and measurement of lipid peroxidation, with additional focus on the p53-SLC7A11 pathway.
    • Lipid metabolite analysis: Mass spectrometry was performed to quantify 12-HETE and other oxylipin levels in culture supernatants.
    • Signal transduction evaluation: Downstream activation of the Gs protein-coupled receptor (GsPCR)-PI3K-Akt pathway by 12-HETE was investigated with pharmacological inhibitors and Western blotting for pathway components.
    • In vivo tumor modeling: Orthotopic xenograft models in immunodeficient mice were used to assess how ALOXE3 knockdown impacts tumor growth and animal survival.

    This integrated approach allowed the authors to causally link miR-18a–mediated ALOXE3 suppression to altered cell death sensitivity and enhanced migratory capacity in GBM.

    Core Findings and Why They Matter

    The study’s most impactful findings include:

    • ALOXE3 is significantly down-regulated in GBM tissues relative to normal brain, correlating with increased miR-18a expression (Yang et al., 2021).
    • miR-18a directly binds the 3'-UTR of ALOXE3 mRNA, leading to its translational repression and protein depletion in GBM cells.
    • Knockdown of ALOXE3 promotes GBM cell survival by conferring resistance to p53-SLC7A11-dependent ferroptosis, suggesting that ALOXE3 is a key mediator of this cell death pathway.
    • ALOXE3 deficiency enhances secretion of 12-HETE, which acts in an autocrine manner to activate the GsPCR-PI3K-Akt signaling axis, thereby stimulating GBM cell migration.
    • In vivo, ALOXE3 knockdown increases tumor growth and reduces survival in orthotopic GBM mouse models.

    The convergence of these findings highlights the miR-18a/ALOXE3 axis as a dual regulator of ferroptotic cell death and tumor invasiveness. Notably, the study demonstrates that lipid metabolic enzymes not only modulate cell survival via ferroptosis but also influence cell motility through paracrine/autocrine activation of GPCR-linked signaling. This mechanistic insight underscores the complexity of cancer cell adaptation and identifies potential molecular targets for intervention.

    Comparison with Existing Internal Articles

    Several recent reviews and research summaries align with and contextualize the findings of Yang et al.:

    This collective body of work strengthens confidence in the significance of the miR-18a/ALOXE3 axis and supports further exploration of signal transduction modulators in GBM research.

    Limitations and Transferability

    Although the study employs robust genetic and pharmacological tools, several caveats should be considered:

    • Clinical heterogeneity: GBM is highly diverse at the molecular level, and the miR-18a/ALOXE3 axis may not be uniformly dysregulated across all patient subtypes.
    • Model system limitations: Most functional studies were performed in established cell lines and immunodeficient mouse models, which may not fully recapitulate the tumor microenvironment of human GBM.
    • Pathway specificity: While the link between ALOXE3 and ferroptosis is well-supported, other compensatory mechanisms could also modulate cell death and migration in vivo.
    • Therapeutic translation: Direct targeting of miRNAs or specific lipid metabolic enzymes remains experimentally challenging, with safety and delivery barriers yet to be overcome.

    Nonetheless, the study provides a strong platform for future translational research, particularly in developing strategies to restore ferroptotic sensitivity or disrupt pro-migratory signaling in GBM.

    Protocol Parameters

    • miR-18a modulation: Use synthetic miR-18a mimics or inhibitors at 50–100 nM for 24–48 hours in GBM cell lines to assess effects on ALOXE3 expression and ferroptosis sensitivity.
    • ALOXE3 knockdown: Transfect cells with siRNA targeting ALOXE3 (10–50 nM) for 48 hours to model enzyme deficiency and measure downstream lipid metabolites.
    • Ferroptosis induction: Treat cells with erastin (1–10 μM) or RSL3 (0.1–1 μM) for 24 hours to evaluate ferroptotic cell death, in combination with ALOXE3 modulation.
    • Lipid metabolite quantification: Collect supernatants and analyze 12-HETE levels using LC-MS/MS protocols standardized for oxylipin detection.
    • GsPCR-PI3K-Akt pathway interrogation: Apply pharmacological inhibitors such as LY294002 (PI3K inhibitor, 10 μM) to validate pathway involvement downstream of 12-HETE stimulation.
    • In vivo assessment: Orthotopic implantation of 1–5 x 105 GBM cells with stable ALOXE3 knockdown into immunodeficient mice; monitor survival and tumor growth using MRI or bioluminescence imaging.

    Research Support Resources

    To experimentally probe G protein-coupled signaling in the context of glioblastoma or related models, researchers may incorporate well-characterized modulators such as Melittin (SKU B6628, APExBIO). Melittin is a bioactive peptide that selectively inhibits Gs protein activity while stimulating Gi protein signaling, thus enabling precise dissection of GPCR-mediated pathways relevant to apoptosis research, signal transduction modulation, and cancer biology. Its high solubility in aqueous solutions and compatibility with cell-based assays make it a versatile resource for investigating cellular response mechanisms. For best results, freshly prepared solutions and recommended storage practices should be followed, as detailed in the product information.